<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619926</url>
  </required_header>
  <id_info>
    <org_study_id>STSP-0601-03</org_study_id>
    <nct_id>NCT05619926</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor</brief_title>
  <official_title>A Multi-center, Open-label, Multiple-dose Design, Phase 2 Trial to Evaluate the Safety and Efficacy of STSP-0601 for Injection in Patients With Hemophilia Without Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staidson (Beijing) Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Novikang Medical Technology Co., LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Staidson (Beijing) Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety,efficacy,pharmacokinetics and pharmacodynamics of&#xD;
      multiple-dose of STSP-0601 at two dose levels for the treatment of bleeding episodes in&#xD;
      hemophilia A or B patients without inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2023</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From day 0 to up to day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of successfully treated bleeding episodes</measure>
    <time_frame>8 hours after first administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of successfully treated bleeding episodes</measure>
    <time_frame>12 hours，24 hours after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of bleeding episodes received salvage treatment</measure>
    <time_frame>Within 3 months after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Consecutive doses of low-dose of STSP-0601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Consecutive doses of high-dose of STSP-0601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSP-0601 for Injection</intervention_name>
    <description>Intravenous Injection</description>
    <arm_group_label>Consecutive doses of high-dose of STSP-0601</arm_group_label>
    <arm_group_label>Consecutive doses of low-dose of STSP-0601</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 ≤age≤70 years of age,male;&#xD;
&#xD;
          -  Hemophilia A or B patients;&#xD;
&#xD;
          -  A bleeding event requiring treatment occurred (Only applicable to the on-demand&#xD;
             treatment stage);&#xD;
&#xD;
          -  Factor VIII or IX level &lt;2%, inhibitor titer &lt; 0.6 BU;&#xD;
&#xD;
          -  There were at least 2 bleeding events that requiring treatment occurred in the past 6&#xD;
             months before screening (Only the second stage is applicable);&#xD;
&#xD;
          -  Establish proper venous access;&#xD;
&#xD;
          -  Agree to use adequate contraception to avoid pregnancy;&#xD;
&#xD;
          -  Provide signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any coagulation disorder other than hemophilia;&#xD;
&#xD;
          -  Plan to receive prophylactic treatment of coagulation factor during the trail;&#xD;
&#xD;
          -  4 weeks before screening, receive prophylactic treatment of amesetuzumab or plan to&#xD;
             receive prophylactic treatment of amesetuzumab during the trial;&#xD;
&#xD;
          -  Patients received anticoagulant or antifibrinolytic therapy 7 days before enrollment&#xD;
             or plan to receive these drugs during the trial;&#xD;
&#xD;
          -  Patients received anticoagulation therapy (such as coagulation factor replacement&#xD;
             therapy, prothrombin complex, plasma, etc.) 7 days before enrollment;&#xD;
&#xD;
          -  Have a history of arterial and/or venous thrombotic events;&#xD;
&#xD;
          -  Platelet &lt;100×109/L;&#xD;
&#xD;
          -  Hemoglobin&lt;90g/L;&#xD;
&#xD;
          -  Severe liver or kidney disease;&#xD;
&#xD;
          -  Severe bleeding event occurred within 4 weeks before enrollment;&#xD;
&#xD;
          -  Accepted major operation or blood transfusion within 4 weeks before enrollment;&#xD;
&#xD;
          -  HIV positive;&#xD;
&#xD;
          -  Have a known allergy to STSP-0601;&#xD;
&#xD;
          -  Participate in other clinical research within 4 weeks before enrollment(except for&#xD;
             participating in prothrombin complex, FVII, FVIIa, FVIII, FIX trails);&#xD;
&#xD;
          -  Patients not suitable for the trail according to the judgment of the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliation:Hospital of Hematology, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanli Wang</last_name>
    <phone>010-67519614</phone>
    <email>wangyanli@staidson.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Hematology, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Zhang</last_name>
      <phone>022-23909095</phone>
      <email>zhanglei1@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>January 18, 2023</last_update_submitted>
  <last_update_submitted_qc>January 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

